NEW YORK, NY - January 16, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST).
CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION
If you have information that could assist in the Aquestive investigation or you are an investor in Aquestive and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.
Aquestive is a pharmaceutical company, focusing on late-stage treatment of central nervous system diseases. The Company is developing Anaphylm, an oral medication designed to treat anaphylaxis and other severe allergic reactions.
On January 9, 2026, before market hours, Aquestive announced in a press release that they are in “receipt of FDA letter stating it has deficiencies that preclude labeling discussions for Anaphylm at this time.” The President and Chief Executive Officer, Dan Barber, further stated that “[a]s part of its ongoing review of the Company’s NDA for Anaphylm, the FDA notified us that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time.”
Following this news, the price of Aquestive stock declined from a closing price on January 8, 2025 of $6.21 per share, to close at $3.91 per share on January 9, 2025, a decline of $2.30 per share, or 37.04%.
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/aquestive-therapeutics-inc/
View the original release on www.newmediawire.com
